{"id":3846,"date":"2025-05-13T17:38:41","date_gmt":"2025-05-13T14:38:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3846"},"modified":"2025-05-13T17:47:11","modified_gmt":"2025-05-13T14:47:11","slug":"elevidys-gene-therapy-approved-in-japan","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/elevidys-gene-therapy-approved-in-japan\/","title":{"rendered":"Sarepta Therapeutics gibt die Zulassung von ELEVIDYS, einer Gentherapie zur Behandlung der Duchenne-Muskeldystrophie, in Japan bekannt"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Personen im Alter von 3 bis unter 8 Jahren, die keine Deletionen in den Exonen 8 und\/oder 9 des DMD-Gens aufweisen und negativ auf Anti-AAVrh74-Antik\u00f6rper getestet wurden, k\u00f6nnen ELEVIDYS anwenden. Dies ist die erste weltweite Zulassung f\u00fcr Personen unter vier Jahren.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr erfahren:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/de\/frequently-asked-questions-about-elevidys-used-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">H\u00e4ufig gestellte Fragen zur Anwendung von Elevidys bei Muskeldystrophie Duchenne<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Gentherapie ELEVIDYS in Japan zugelassen<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sarepta Therapeutics, der f\u00fchrende Anbieter auf dem Gebiet der Pr\u00e4zisionsgenetik f\u00fcr seltene Krankheiten, gab heute bekannt, dass das japanische Ministerium f\u00fcr Gesundheit, Arbeit und Soziales (MHLW) ELEVIDYS (Delandistrogenmoxeparvovec) im Rahmen des bedingten und zeitlich begrenzten Zulassungsverfahrens in Japan zur Behandlung der Duchenne-Muskeldystrophie (DMD) zugelassen hat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr lesen:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/de\/will-elevidys-receive-approval-from-the-european-medicines-agency-ema\/\">Wird Elevidys die Zulassung der Europ\u00e4ischen Arzneimittel-Agentur (EMA) erhalten?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>People aged 3 to under 8 who do not have deletions in exons 8 and\/or 9 of the DMD gene and who test negative for anti-AAVrh74 antibodies are eligible to use ELEVIDYS. This is the first worldwide approval that covers people under the age of four. Learn More: Frequently Asked Questions About Elevidys Used for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3847,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[33,61,142],"class_list":["post-3846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevidys","tag-gene-therapy","tag-japan"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=3846"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/3847"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=3846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=3846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=3846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}